Document Detail


Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management.
MedLine Citation:
PMID:  21985166     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Pregnancy can pose a challenge to the physician caring for women with rheumatoid arthritis (RA). While many women with RA experience a spontaneous improvement in joint pain and inflammation during pregnancy, in others it remains active and they continue to need ongoing therapy. It is important to tailor the treatment regimen so that the disease is stabilized prior to conception and to use medications that are safe throughout pregnancy and lactation. The use of immunomodulating medications considered low risk during pregnancy allows for optimal outcomes. NSAIDs should be avoided in the third trimester. Corticosteroids may be used throughout pregnancy in the lowest effective dose. Antimalarial agents, sulfasalazine and azathioprine are safe options, but methotrexate and leflunomide are contraindicated as they are teratogenic and must, therefore, be withdrawn before a planned pregnancy. The risk for some of the newer biological therapies for RA is not necessarily their proven teratogenicity, but the absence of proven safety for the fetus. As such, it is recommended that abatacept, rituximab and tocilizumab be withheld prior to pregnancy; however, tumour necrosis factor inhibitors and anakinra may be continued until conception. In this review, we provide an overview of the RA treatment issues pre-conception, during pregnancy and in the post-partum period with respect to breastfeeding, and we provide guidelines for drugs that may be used relatively safely for RA management in pregnant women. Where available, pre-conception guidelines for men using these medications for RA are also discussed.
Authors:
Ashima Makol; Kerry Wright; Shreyasee Amin
Related Documents :
24759226 - Maternal-fetal cellular trafficking: clinical implications and consequences.
24218266 - Purification of native surfactant protein sp-a from pooled amniotic fluid and bronchoal...
23703536 - Downregulated kruppel-like factor 8 is involved in decreased trophoblast invasion under...
22215706 - Transcriptionally active syncytial aggregates in the maternal circulation may contribut...
24916516 - Do we need readjustment of the biochemical parameters in first trimester combined aneup...
1710066 - Human chorionic gonadotrophin and alpha-fetoprotein levels in matched samples of amniot...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs     Volume:  71     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1973-87     Citation Subset:  IM    
Affiliation:
Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vitamins and Cognition: What is the Evidence?
Next Document:  Therapeutic potential of ginseng in the management of cardiovascular disorders.